DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions
Open Access
- 7 March 2022
- journal article
- review article
- Published by Wiley in Aging and Cancer
- Vol. 3 (1) , 44-67
Abstract
DNA molecules are subject to various lesions that can be detrimental to the cells. DNA damage response (DDR) pathways encompass a variety of mechanisms that cells employ in response to DNA damage. While DDR promotes genomic stability in normal cells, it also protects cancer cells from DNA lesions, particularly against exogenous DNA‐damaging agents. Therefore, DDR pathways can be exploited to account for resistance to chemotherapy and radiotherapy and have the potential to be targeted in cancer treatment. Apart from the poly (ADP‐ribose) polymerase (PARP) inhibitors used in BRCA‐mutant cancers, other DDR inhibitors are being developed and tested in clinical trials. Based on the synthetic lethality theory, combination therapies utilizing DDR inhibitors have been explored and are currently undergoing clinical trials, with promising results in cancer treatment. Combination therapies typically employ a DDR inhibitor to sensitize cancer cells to traditional chemotherapeutic agents, radiotherapy, immunotherapy, and even PARP inhibitors. Herein, we focus on recent advances in DDR inhibitor‐based combination therapies other than PARP inhibitors, explore the advantages and disadvantages of the strategies, and discuss the current challenges and future perspectives.Keywords
Funding Information
- National Natural Science Foundation of China (81827804)
This publication has 152 references indexed in Scilit:
- Genetic Interactions in Cancer Progression and TreatmentCell, 2011
- BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viabilityJournal of Molecular Cell Biology, 2011
- Apurinic/apyrimidinic endonuclease is inversely associated with response to radiotherapy in pediatric ependymomaInternational Journal of Cancer, 2011
- The DNA Damage Response: Making It Safe to Play with KnivesMolecular Cell, 2010
- Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]The Journal of Pharmacology and Experimental Therapeutics, 2009
- The DNA-damage response in human biology and diseaseNature, 2009
- γH2AX and cancerNature Reviews Cancer, 2008
- Mammalian single-strand break repair: Mechanisms and links with chromatinDNA Repair, 2007
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005